Moleculin Biotech
Climate Impact & Sustainability Data (2024)
Reporting Period: 2024
Environmental Metrics
Climate Goals & Targets
Short-term Goals:
- Announce first patient treated in MIRACLE trial in Q1 2025
- Provide a peak at data by the end of 2025
Environmental Challenges
- Market in general is terrible
- Concern for financing overhang
- Lack of investor interest due to focus on targeted therapies
Mitigation Strategies
- KOL event to highlight Annamycin's potential
- Focus on Annamycin's unique attributes (non-cardiotoxic, lack of cross-resistance)